Related Experiment Videos
Hypoxic-ischemic brain damage in perinatal age group
1Michigan State University, East Lansing 48824, USA. kumark@pilot.msu.edu
Insights
Perinatal hypoxic-ischemic brain injury causes lifelong disability. Research explores therapies like amino acid antagonists and hypothermia, but neonatal trials face challenges.
Area of Science:
- Neurology
- Pediatrics
- Neonatology
Background:
- Perinatal hypoxic-ischemia is a leading cause of childhood neurological deficits.
- Understanding injury mechanisms has spurred therapeutic research.
Purpose of the Study:
- To review current knowledge on hypoxic-ischemic brain injury mechanisms.
- To discuss potential therapeutic strategies for neonatal application.
- To highlight challenges in neonatal clinical trials.
Main Methods:
- Review of existing research on hypoxic-ischemic brain injury.
- Analysis of potential therapeutic agents and their mechanisms.
- Discussion of clinical trial progress and limitations.
Main Results:
- Several therapeutic approaches are under investigation, including excitatory amino acid antagonists, calcium channel blockers, free-radical scavengers, nitric oxide synthase inhibitors, anti-inflammatory agents, trophic factors, and hypothermia.
- Some agents are in adult clinical trials, but neonatal trials are slow due to safety concerns and developmental complexities.
- Identifying and controlling risk factors is crucial for prevention, especially in resource-limited settings.
Conclusions:
- Effective neonatal therapeutic interventions require large, multicenter trials.
- Prevention through risk factor control is paramount.
- Further research is needed to bridge the gap between adult and neonatal therapeutic applications.
Abstract:
Cerebral hypoxia-ischemia in the perinatal period continues to be a major contributor to chronic neurologic impairment in children worldwide. Extensive research conducted in the past several years has led to a better understanding of the mechanisms involved in hypoxic-ischemic brain injury. Based on this understanding, the major potential therapeutic approaches being studied include antagonists of excitatory amino acids, calcium channel antagonists, free-radical scavengers, nitric oxide synthase inhibitors, anti-inflammatory agents, trophic factors, and hypothermia. Several agents are in clinical trial phases in adults. However, safety concerns and close relationship between pathomechanisms of hypoxic-ischemic cerebral injury and normal developmental processes have contributed to the slow pace in the neonatal trials. Large multicenter trials including an adequate number of infants will be needed to evaluate efficacy of therapeutic interventions in this particular age group. A large number of risk factors that predispose to hypoxic ischemic injury have been identified. It is important to control these factors and prevent brain damage in the first place. This is especially true for developing countries where resources for treatment with newer agents (when they become available) are likely to be limited. Recent information regarding mechanisms of injury and potential therapeutic measures related to perinatal age are presented in this paper.